옵션 체인은 다양한 행사가격과 만기일에 대한 Candel Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Candel Therapeutics에 대한 시장 심리를 평가합니다..

Candel Therapeutics (NASDAQ:CADL) 주식, 옵션 체인

CANDEL THERAPEUTICS INC

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

3 Stocks With Strong Fundamentals Analysts Recommend For Long-Term Success

Equities

News

Markets

ADBE

CADL

TSLA

수요일(11일) 미국 증시는 최근의 인플레이션 보고서에 힘입어 낙관적인 분위기를 보였다. 나스닥 100 지수는 1.7% 급등하여 새로운 최고치를 기록했고, S&amp;P 500 지수는 0.8% 상승했다. 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

수요일 주목받은 주식: 게임스탑, 어도비, 메타, 캔델 테라퓨틱스 및 테슬라

Stocks Photo by Phongphan on Shutterstock

NVDA

PLTR

미국 주식 시장은 목요일에 하락하며, 다우존스 지수는 1.35% 하락한 38,596.98에 도달했다. NASDAQ와 S&amp;P 500도 각각 1.4% 하락한 16,049.08과 1.23% 하락한 5,147.21을 기록했다. 전체 시장의 하락에도 불구하고, 일부 종목은 소매 트레이더와 투자자들의 주목을 끌었다.



하루 내내 소매 트레이더와 투자자들의 관심을 끌은 주요 주식은 다음과

목요일의 주요 주식: 포드, 캔들 테라퓨틱스, 엔비디아, 팔란티어, 테슬라

Candel Therapeutics Inc

Cadeler AS

Government

Regulations

SCNI

Scinai Immunotherapeutics Receives Italian Government Clearance To Potentially Acquire Pincell S.r.l.

Silynxcom Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NYSE">SYNX</a>) ("Silynxcom" or the "Company"), a manufacturer and developer of ruggedized tactical communication headset devices, today announced that it has received a $140,000 purchase order from a special forces unit in the Asia-Pacific region for its advanced in-ear communication systems.
The Company believes that this order reinforces Silynxcom's expanding global footprint and the growing demand for its cutting-edge communication solutions among elite military units worldwide. The Company's in-ear headset systems are renowned for their durability, advanced technology, and critical in-ear sound protection, making them a preferred choice for defense organizations operating in challenging environments.
The Company continues to strengthen its position in the specialized tactical communications market, with recent orders from elite units in various regions, including the Israel Defense Forces and European special forces units.

SYNX

Silynxcom Receives $140K Purchase Order From Special Forces Unit In Asia-Pacific Region For Advanced In-Ear Communication Systems

Lands' End, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) shares are trading higher after the company reported<a href="https://www.benzinga.com/pressreleases/25/06/g45788593/lands-end-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener"> first-quarter fiscal year 2025 earnings</a>.
Here&#8217;s a breakdown of the results:
<ul class="wp-block-list">
<li>Net revenue was&nbsp;$261.2 million,&nbsp;missing the analyst consensus of&nbsp;$272.6 million.</li>
<li>Gross Merchandise Value (GMV) rose by a low-single-digit percentage in the first quarter (excluding a $12.7 million impact from shifting kids and footwear inventory to licensees).</li>
<li>Including this transition, GMV saw a slight Y/Y decline, while like-for-like GMV increased in the quarter by low single digits.</li>
<li>Adjusted loss per share was 18 cents which <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">came in line with the consensus</a>.</li>
<li>US eCommerce Net revenue was&nbsp;$170.7&nbsp;million, broadly flat year over year (Y/Y) in the quarter as strong Outerwear product performance was offset by a slower start to the seasonal swim assortment.</li>
<li>Outfitters net revenue was&nbsp;$42.9&nbsp;million, an increase of&nbsp;0.5% Y/Y. Third-party net revenue was&nbsp;$14.1&nbsp;million, a decrease of&nbsp;9.0%&nbsp;Y/Y in the quarter.</li>
<li>Gross profit decreased 4.5% year over year to $132.7 million, with gross margin rising by around 210 basis points year over year to 50.8%. The gross margin improved mainly due to transitioning kids&#8217; and footwear inventory to licensees in the first quarter of 2024.</li>
</ul>
Buyback: In the&nbsp;first quarter, the company bought back&nbsp;$2.8&nbsp; million&nbsp;worth of its common stock under the share repurchase program announced on March 15, 2024.
As of May 2, the program allows for up to $10.6 million in additional stock repurchases through March 31, 2026. Cash and cash equivalents totaled $18.1 million.
Outlook: Lands' End reaffirmed its FY25 guidance. It projects adjusted EPS between 48 cents and 86 cents, compared to <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">the 70 cents consensus estimate</a>.
The company, currently up for sale, maintains its sales outlook of $1.33 billion to $1.45 billion versus $1.38 billion estimate.
CFO Bernie McCracken said the company developed plans to &#8220;mitigate&#8221; tariff headwinds.
&#8216;This outlook assumes a baseline tariff of approximately 10% in all countries except China, McCraken explained. China accounts for less than 8% of the company&#8217;s product cost in 2024, where Lands&#8217; End assumes a 30% tariff.
Price Action: LE shares are up 7.46% at $8.50 during Thursday&#8217;s premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44362190/lands-end-has-strengthened-catalog-strategy-to-embrace-younger-audience-says-analyst" target="_blank" rel="noreferrer noopener">Lands&#8217; End Strengthens Catalog Strategy To Embrace Younger Audience, Says Analyst</a></li>
</ul>
Image: Shutterstock

Outerwear Strong, Swim Slow: Lands' End Navigates Q1, Seeks Sale Options

<a href="https://www.bloomberg.com/news/articles/2025-06-05/trump-xi-speak-amid-trade-technology-dispute-xinhua-says?srnd=homepage-canada" title="https://www.bloomberg.com/news/articles/2025-06-05/trump-xi-speak-amid-trade-technology-dispute-xinhua-says?srnd=homepage-canada">https://www.bloomberg.com/news/articles/2025-06-05/trump-xi-speak-amid-trade-technology-dispute-xinhua-says?srnd=homepage-canada</a>

Macro Economic Events

Politics

Global

Economics

General

'Trump, Xi Speak Amid Trade, Technology Dispute, Xinhua Says' - Bloomberg News

Mullen Automotive Acquires Additional Bollinger Motors Shares, Ownership Stake at 95%; Companies Continue Full Commitment to EV Customers, Vehicle Service

Legal

MULN

Mullen Automotive Increases Ownership Stake Into Bollinger Motors To 95% As Part Of Settlement

UBS analyst Karl Keirstead maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Neutral and raises the price target from $213 to $240.

Price Target

Analyst Ratings

UBS Maintains Neutral on MongoDB, Raises Price Target to $240

OMI Remains Committed to Continued Growth in the Strong Home-based Care Market
Will Focus on Deleveraging &amp; Driving Profitable Growth
Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>)today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens &amp; Minor has paid $80 million to Rotech Healthcare. Owens &amp; Minor will also redeem the $1 billion of notes issued in April 2025, which include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders which would have been utilized to consummate the acquisition.

Owens & Minor Terminates Rotech Healthcare Acquisition, Redeems $1B Notes & Cancels Loan Commitments

UBS analyst Michael Lasser maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Buy and raises the price target from $110 to $160.

FIVE

UBS Maintains Buy on Five Below, Raises Price Target to $160

American Rebel Light Beer Expanded Presence in Nashville, Motorsports (NHRA) &amp; Music Events—Fueling Surging Demand for America's Patriotic Beer

AREB

American Rebel Light Beer Completes Production Run To Meet Demand

Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million&nbsp;from the sale of shares of the company's common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions.
Ladenburg Thalmann &amp; Co. Inc. is acting as the exclusive placement agent for the offering.
The agreements provide for the immediate exercise of certain outstanding warrants to purchase an aggregate of 8,301,322 shares of common stock, issued by the company on June 5, 2020, October 25, 2022 and July 21, 2024 (the "Existing Warrants"), at a reduced exercise price of $0.3041 per share. The shares of common stock issuable upon exercise of the Existing Warrants are all registered, or their resale is registered, pursuant to effective registration statements. The company did not issue any replacement warrants. The gross proceeds to the company from the exercise of the Existing Warrants are expected to be approximately $2.5 million, prior to deducting placement agent fees and offering expenses. The company intends to use the net proceeds for general corporate purposes, including working capital and operating expenses.

CLRB

Cellectar Biosciences Enters Into Definitive Agreements To Raise $2.5M From Sale Of Shares Priced At-Market For Nasdaq Purposes

Callan JMB redistributed more than 1,300 vaccine doses using its specialized cold chain reusable shippers from Westside CDC in Chicago to Texas and New Mexico, ensuring no vaccines went to waste
All of the shippers used in the distribution of the vaccines were recovered and recertified for reuse, resulting in none going into landfills

Biotech

CJMB

Callan JMB Redistributes MMR II Vaccines

Upexi, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that options on its common stock are approved for trading on the Nasdaq Options Market.
The options will trade under the ticker symbol "UPXI" and include a range of standard expiration dates and strike prices. The listing of options on UPXI shares provides investors with additional tools for managing risk and capitalizing on the Company's performance and future growth prospects.
Options trading is expected to support broader investor participation and flexibility. Investors can access UPXI options through major brokerage platforms and trading networks that support equity options on the Nasdaq exchange.

UPXI

Upexi Says Options On Common Stock Approved For Trading On Nasdaq Options Market

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (<a href="https://www.globenewswire.com/Tracker?data=jhFVTwBRSpyt4OQmZ3sjaPfrAPSQRPJe15SBX-yTiX9JukNvIPpsQtcsJScXFHpBtbFRkQW5aGu939DQaUCQKeYuEoUd2IWkOjiRyI6m7NM=">https://bpsasm.org/</a>) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain.
Professor Saoirse O'Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: "The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain." The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain.
Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo's FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks.
Professor O'Sullivan stated, "ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically."
Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain.
OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases.

ARTL

Artelo Biosciences Presents New Data At British Pain Conference That Further Validates Therapeutic Potential Of Fatty Acid Binding Protein Inhibitors In Treating OA Pain

Across the recent three months, 11 analysts have shared their insights on Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $49.27, a high estimate of $59.00, and a low estimate of $43.00. Highlighting a 5.74% decrease, the current average has fallen from the previous average price target of $52.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1749128490_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Schlumberger is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Schlumberger. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Schlumberger compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Schlumberger's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Schlumberger's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Schlumberger analyst ratings.</a>
<h2>About Schlumberger</h2>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts roughly $3 billion in digital-related revenue.
<h3>Key Indicators: Schlumberger's Financial Health</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Schlumberger's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -2.49%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Schlumberger's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Schlumberger's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.92%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Schlumberger's ROA stands out, surpassing industry averages. With an impressive ROA of 1.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.72, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Schlumberger Through The Eyes Of 11 Analysts

Bitwise CEO Hunter Horsley says 2025 marks a "watershed year" for crypto as regulatory clarity, <a href="https://www.benzinga.com/25/05/45521682/bitcoin-soars-to-105125-amid-institutional-investments-x-founder-proposes-btc-rebrand">institutional adoption</a> and mainstream political support converge to reshape the investment landscape for digital assets.
What Happened: Speaking with <a href="https://www.youtube.com/watch?v=tt4_KY8MvxY">CNBC</a> at the Bitcoin Conference 2025, Horsley emphasized that the most significant overhang on crypto markets, regulatory uncertainty, has flipped from a headwind into a tailwind.
"2025 is a watershed year… it's absolutely the beginning of a new chapter for the space," he said, pointing to regulatory support from the White House, Congress, and financial regulators as a turning point.
For years, ambiguity from U.S. regulators prevented institutional investors from meaningfully participating in crypto. "It's finally an asset class that they can engage in," Horsley said. 
The result: mainstream investors are now entering the space in force. In Q1 alone, 190 new wealth firms invested in Bitwise products for the first time.
This changing backdrop has fueled Bitcoin's latest all-time high near $112,000, but Horsley argues the real significance lies beneath the surface. 
"The biggest risk of the space has been removed," he said, referring to the resolution of regulatory uncertainty. With that barrier gone, he believes the opportunity for institutional capital deployment is just beginning.
That optimism is supported by Bitwise's own growth. 
The firm manages over $12 billion in assets across ETFs, hedge funds, and crypto income products. 
Horsley also pointed to recent milestones, such as a $600 billion wealth manager approving Bitwise's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs, as evidence that regulated institutions are moving in.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45777944/jpmorgan-to-accept-crypto-linked-etfs-as-loan-collateral">JPMorgan To Accept Crypto-Linked ETFs As Loan Collateral</a>
What&#8217;s Next: Looking ahead, <a href="https://www.benzinga.com/25/05/45560419/trumps-crypto-czar-david-sacks-foresees-stablecoin-bill-generating-trillions-for-us-treasury-practically-overnight">stablecoin legislation is on the horizon</a>.
The Senate's advancement of the bipartisan Genius Act signals growing alignment in Washington, and Horsley says lawmakers are now actively responding to constituent demand. 
"100 million Americans want to see Bitcoin and crypto flourish in America," he said, noting that regulatory clarity is essential and not optional for mass adoption.
Horsley also echoed Bitwise CIO Matt Hougan's view that stablecoin regulation could be the most important development in crypto's history. 
While the approval of spot Bitcoin ETFs in January 2024 was transformative, Horsley believes clear legal frameworks are what will ultimately mainstream the asset class.
He compared the current moment to the early days of the iPhone: underappreciated at first, but quickly becoming indispensable once adopted. 
"People are going to be surprised when they start seeing Bitcoin at companies that are not crypto companies," he said.
Bitwise and UTXO Management recently projected over $400 billion in institutional inflows into Bitcoin by the end of 2026. 
Horsley attributes this to the sheer size of traditional capital markets, which until recently had no path to crypto exposure. 
"98% of all Bitcoin that will ever exist has already been mined, and yet 98% of all the capital in the capital markets does not yet own any crypto," he said.
As wealth firms shift from 1% allocations toward 5% or more, Horsley believes the coming wave of capital could exceed most expectations. 
"It's not the old school Bitcoin anymore," he said. "You're going to see financial institutions, banks, and tech companies all building services and launching products."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">Pump.fun&#8217;s $1B Token Plan Risks Undermining Solana DeFi, Fueling Meme Coin Scams, Experts Warn</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bitcoin Adoption Makes 2025 A 'Watershed Year' For Crypto, Bitwise CEO Hunter Horsley Says

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for NOV, revealing an average target of $16.0, a high estimate of $23.00, and a low estimate of $10.00. A 9.3% drop is evident in the current average compared to the previous average price target of $17.64. 
<img src="https://www.benzinga.com/files/images/story/2025/1749128478_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of NOV among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Luke Lemoine</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NOV. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of NOV compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of NOV's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of NOV's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NOV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NOV analyst ratings.</a>
<h2>Discovering NOV: A Closer Look</h2>
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
<h3>Financial Insights: NOV</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining NOV's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.41% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: NOV's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.14%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): NOV's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.65%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NOV's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About NOV Stock

Across the recent three months, 5 analysts have shared their insights on Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myomo and provided 12-month price targets. The average target is $10.6, accompanied by a high estimate of $11.50 and a low estimate of $9.50. This current average has increased by 11.58% from the previous average price target of $9.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1749128461_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Myomo by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Woo</td>
<td>Ascendiant Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.50</td>
<td>$11.00</td>
</tr>
<tr>
<td>Craig Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward Woo</td>
<td>Ascendiant Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Craig Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Myomo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myomo compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Myomo's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Myomo's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MYO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myomo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Myomo</h2>
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
<h3>Understanding the Numbers: Myomo's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Myomo's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 161.88% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Myomo's net margin is impressive, surpassing industry averages. With a net margin of -35.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Myomo's ROE excels beyond industry benchmarks, reaching -14.94%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Myomo's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -8.34%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Myomo's debt-to-equity ratio is below the industry average at 0.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Myomo Stock: Analyst Perspectives (5 Ratings)

Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) meteoric growth in the last few years has changed fortunes, influenced perceptions, and positioned it as one of the most sought-after assets, alongside traditional heavyweights such as stocks and gold.
Investors who bought into the cryptocurrency early are now laughing their way to the bank.
What happened: Back in 2020, Tesla and SpaceX CEO Elon Musk made a playful endorsement of Bitcoin in an X (formerly Twitter) post.
The tech mogul wrote, "Bitcoin is my safe word," in a post dated Dec. 20, in what seemed like a sexually suggestive reference.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin is my safe word
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1340573003579617280?ref_src=twsrc%5Etfw">December 20, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Soon, an army of people swarmed to his message, some wholeheartedly agreeing and others dismissing his remark.
While the post was not a direct investment call, it came during a period of rapid growth for Bitcoin. The apex cryptocurrency had just crossed $20,000 for the first time, a big leap from $7,000 at the start of the year.
On that day of the post, the price of Bitcoin was about $23,861.77 per coin. Let's say you got swayed by Musk's comment and immediately decided to invest $1000 in the asset. It would have fetched you 0.04190 BTC.
Fast forward to June 2025. BTC is trading at $104,542.75, meaning that the original investment would have turned into $4381.18, netting you a return of 338%.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740537/forget-dollars-willy-woo-says-bitcoin-will-be-priced-against-global-gdp-gold-used-to-be-that-money-btc-is-the-challenger">Forget Dollars: Willy Woo Says Bitcoin Will Be Priced Against Global GDP — &#8216;Gold Used To Be That Money, BTC Is The Challenger&#8217;</a>
Congratulations if you actually invested! If not, it may be a good time to recall phrases such as &#8220;Life is about hits and misses,&#8221; &#8220;There&#8217;s no point in crying over spilled milk,&#8221; and &#8220;Life gives you another chance.&#8221;
Bitcoin, for that matter, continues to balloon, rising 47% over a year and 12% year-to-date.&nbsp;
Even Musk seemed to be becoming serious about the technology. Earlier this week, he announced the launch of the XChat messaging program, claiming to have <a href="https://www.benzinga.com/news/social-media/25/06/45717476/elon-musk-launches-xchat-with-claimed-bitcoin-style-encryption-but-expert-says-its-like-running-a-rocket-on-water">end-to-end encryption similar to Bitcoin</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45739199/american-politicians-dont-believe-bitcoin-can-co-exist-peacefully-with-the-dollar-says-this-popular-btc-maximalist-heres-why">American Politicians Don&#8217;t Believe Bitcoin Can &#8216;Co-Exist Peacefully&#8217; With The Dollar, Says This Popular BTC Maximalist: Here&#8217;s Why</a></li>
</ul>
Photo Courtesy: Paopano on Shutterstock

If You Invested $1000 In Bitcoin When Elon Musk Playfully Said BTC Was His 'Safe Word,' Here's How Much It'd Be Worth Today

12 analysts have shared their evaluations of Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Liberty Energy and provided 12-month price targets. The average target is $17.12, accompanied by a high estimate of $25.00 and a low estimate of $11.00. Experiencing a 13.32% decline, the current average is now lower than the previous average price target of $19.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1749128451_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Liberty Energy's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Sean Meakim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$16.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Liberty Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Liberty Energy compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Liberty Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Liberty Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LBRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Liberty Energy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Liberty Energy: A Closer Look</h2>
Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&amp;P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.
<h3>Key Indicators: Liberty Energy's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Liberty Energy faced challenges, resulting in a decline of approximately -8.91% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Liberty Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.06%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Liberty Energy's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.02%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Liberty Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

12 Analysts Have This To Say About Liberty Energy

Ratings for Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Halliburton and provided 12-month price targets. The average target is $28.09, accompanied by a high estimate of $32.00 and a low estimate of $22.00. Highlighting a 8.05% decrease, the current average has fallen from the previous average price target of $30.55. 
<img src="https://www.benzinga.com/files/images/story/2025/1749128442_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Halliburton among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Halliburton. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Halliburton compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Halliburton's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Halliburton's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Halliburton analyst ratings.</a>
<h2>Delving into Halliburton's Background</h2>
Halliburton is North America's largest oilfield service company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. The firm's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been homed in over a century of operations.
<h3>Understanding the Numbers: Halliburton's Finances</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Challenges: Halliburton's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -6.67%. This indicates a decrease in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Halliburton's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.95%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.8%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Halliburton's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.83, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Halliburton Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Health Care

Press Releases

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics to Present at Upcoming Investor Conferences

Earnings

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

DAWN

OSTX

YMAB

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Astria Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Inozyme Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neurogene

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Solid Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

HC Wainwright & Co.

Canaccord Genuity

Citigroup

B of A Securities

BMO Capital

Screenshot 2024-06-13 at 5.29.56 PM

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Comments

Candel Therapeutics

Candel Therapeutics (CADL) 옵션

Candel Therapeutics (NASDAQ:CADL) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌